BCI
GBT

Brinker Capital Investments’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Brinker Capital Investments’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-5,155
Closed -$284K – 1238
2020
Q3 		$284K Buy
+5,155
New +$328K ﹤0.01% 1020

Other funds holding GBT

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Brinker Capital Investments's GBT Position: Q4 2020 in Review

Brinker Capital Investments sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2020, closing a stake of 5,155 shares — an estimated $284K sold.

Brinker Capital Investments first reported a position in GBT in Q3 2020 and held it in 1 quarter. The position peaked at $284K in Q3 2020. 228 funds tracked by Wall St. Rank hold GBT as of Q4 2020.

  • Brinker Capital Investments reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
  • Brinker Capital Investments sold 5,155 Global Blood Therapeutics, Inc. shares in Q4 2020, an estimated $284K.
  • Brinker Capital Investments first reported a position in Global Blood Therapeutics, Inc. in Q3 2020 and held it in 1 quarter.
  • Brinker Capital Investments's Global Blood Therapeutics, Inc. position peaked at $284K in Q3 2020.
  • 228 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2020.

Based on Brinker Capital Investments's 13F filing for Q4 2020, filed 16 Feb 2021.